Cancer drug safety watch continues for 120 patients
NCT ID NCT04058756
Summary
This study continues monitoring the safety of spartalizumab, an experimental cancer treatment, for patients who were already receiving it in previous Novartis trials. It allows 120 patients with advanced solid tumors to keep getting the treatment while researchers track side effects. The main goal is to understand long-term safety, not to test if the drug works against cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
MD Anderson Cancer Center Uni of Te
Houston, Texas, 77030, United States
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Liège, 4000, Belgium
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Montreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
Guangzhou, Guangdong, 510515, China
-
Novartis Investigative Site
Guangzhou, 510060, China
-
Novartis Investigative Site
Brno, 656 53, Czechia
-
Novartis Investigative Site
Lille, 59037, France
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Marseille, 13885, France
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Ulm, 89081, Germany
-
Novartis Investigative Site
High West, Hong Kong
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Pokfulam, 999077, Hong Kong
-
Novartis Investigative Site
Budapest, H 1122, Hungary
-
Novartis Investigative Site
Debrecen, 4032, Hungary
-
Novartis Investigative Site
Milan, MI, 20132, Italy
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Milan, MI, 20141, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Modena, MO, 41124, Italy
-
Novartis Investigative Site
Aviano, PN, 33081, Italy
-
Novartis Investigative Site
Siena, SI, 53100, Italy
-
Novartis Investigative Site
Naples, 80131, Italy
-
Novartis Investigative Site
Leiden, South Holland, 2333 ZA, Netherlands
-
Novartis Investigative Site
Gdansk, 80-952, Poland
-
Novartis Investigative Site
Poznan, 60-693, Poland
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Valencia, 46010, Spain
-
Novartis Investigative Site
Zurich, 8091, Switzerland
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Songkhla, Hat Yai, 90110, Thailand
-
Novartis Investigative Site
Bangkok, 10330, Thailand
-
Novartis Investigative Site
Chiang Mai, 50200, Thailand
-
Providence Portland Medical Center
Portland, Oregon, 97123, United States
Conditions
Explore the condition pages connected to this study.